Sara Semnani practices corporate and securities law, counseling companies on formation and financing activities, securities law compliance, corporate governance matters and other strategic transactions, with a particular emphasis on representing clients in the life sciences industry. She counsels private companies at all stages, guiding them through their exit, and also focuses on representing issuers in their initial public offerings.

Download full bio 


  • Kyverna Therapeutics Closes $85 Million Series B 

  • The Honest Company – $475 Million IPO 

  • Ovid - $75 Million IPO 

  • Vir Biotechnology - $143 Million IPO 

  • Kezar Life Sciences – $86 Million IPO 

  • View all


  • University of California at Los Angeles School of Law
    JD, 2011

  • University of California, Los Angeles Anderson School of Management
    MBA, 2011

  • University of California, Los Angeles
    BA, 2007

Admissions & Credentials